Wealth Manager - the site for professional investment managers

Register to get unlimited access to Citywire’s fund manager database. Registration is free and only takes a minute.

AstraZeneca rejects final £55 Pfizer offer

AstraZeneca rejects final £55 Pfizer offer

AstraZeneca has turned down a final offer for the company by rival Pfizer saying that the value of £55 per share ‘undervalues the company and its attractive prospects’.

At 8.45 shares in the business were down 14.17% at £41.39 - back where they stood before the bid was announced in April. 

Following a political row over the attempted buyout, Pfizer ruled out taking the bid hostile. The Labour party, which could be in power by the time any potential bid was finalised, has said it would consider a public interest test before offering regulatory approval. 

Following the rejection of the mixed cash and equity offer Astra chair Leif Johansson said: ‘Pfizer's approach throughout its pursuit of AstraZeneca appears to have been fundamentally driven by the corporate financial benefits to its shareholders of cost savings and tax minimisation.

‘From our first meeting in January to our latest discussion yesterday, and in the numerous phone calls in between, Pfizer has failed to make a compelling strategic, business or value case.

‘We have rejected Pfizer's final proposal because it is inadequate and would present significant risks for shareholders, while also having serious consequences for the company, our employees and the life-sciences sector in the UK, Sweden and the US.’

Pfizer had offered £53 per share after markets had closed on Friday. AstraZeneca indicated that it would not consider anything less than a 10% improvement pf those terms.

The company pointed to what it described as a ‘growing and accelerating’ number of drugs close to approval which it believes could have potential sales of up to $23 billion (£13.6 billion) a year.

Leave a comment!

Please sign in or register to comment. It is free to register and only takes a minute or two.
Citywire TV
Play Big City Bright Future

Big City Bright Future

Big City Bright Future, the brainchild of BlackRock, is a three-week work experience programme for school leavers looking to forge a career in the City.

Play Kames' Ennett: Trump good for US high yield, but beware Europe

Kames' Ennett: Trump good for US high yield, but beware Europe

Kames Capital’s head of high yield David Ennett believes the changing political landscape will be a positive for the US, but negative for Europe in 2017.

Play Philip Milburn: why inflation won't run out of control

Philip Milburn: why inflation won't run out of control

Kames bond fund manager views inflation as more of 'scare' than a 'problem' and is positioning his portfolios accordingly.

Read More
Your Business: Cover Star Club

Profile: change is the only constant for Quilter Cheviot

Profile: change is the only constant for Quilter Cheviot

This is not the first time we have profiled David Miller, but at the time of his previous appearance his company looked very different.

Wealth Manager on Twitter